Iron Mountain Inc.
IRM
$0.00
+2.33%
Iron Mountain Inc. is a real estate investment trust specializing in information management and data center services. It is a global leader in secure storage and information lifecycle solutions, serving a diverse client base across multiple industries.
IRM
Iron Mountain Inc.
$0.00
Investment Opinion: Should I buy IRM Today?
Based on a synthesis of the data, the objective assessment is a Hold. The company's strong revenue growth and market leadership are positive, but these are overwhelmingly offset by critical weaknesses in financial health, inconsistent profitability, and a valuation that prices in near-perfect execution. While institutional analysts remain positive, the fundamental data suggests significant risk, making it difficult to recommend a new Buy position at current levels. Investors should await clearer signs of sustained profitability improvement and debt reduction.
Sign up to view all
IRM 12-Month Price Forecast
The AI assessment is neutral due to conflicting signals. The strong operational growth and recovery momentum are compelling, but they are fundamentally undermined by poor financial health metrics and a valuation demanding flawless execution. The high probability is assigned to a base case of sideways movement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Iron Mountain Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
3 analysts
Implied Upside
—
vs. current price
Analyst Count
3
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst data for specific target prices and ratings distribution is not available in the provided inputs. However, recent institutional ratings from firms like Barclays and JP Morgan consistently maintain 'Overweight' or 'Buy' recommendations. No sufficient analyst coverage data for a detailed consensus is available.
Bulls vs Bears: IRM Investment Factors
Iron Mountain presents a mixed picture. Strong revenue growth and positive institutional sentiment are countered by severe financial strain and a valuation that appears stretched. The stock's recent recovery is notable but faces headwinds from its balance sheet.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 16.56% YoY, indicating robust demand.
- Positive Analyst Sentiment: Institutions like Barclays maintain 'Overweight' or 'Buy' recommendations.
- Recovery and Outperformance: Stock up 23.13% over 3 months, significantly beating the S&P 500.
- Solid Operating Margin: Operating margin of 20.36% shows core business profitability.
Bearish
- Extremely High Valuation: Trailing P/E of 169.5 and forward P/E of 39.9 suggest overvaluation.
- Weak Financial Health: Negative debt-to-equity (-19.42) and negative free cash flow (-$931.6M).
- Inconsistent Profitability: Net income fluctuates sharply, with a low trailing net margin of 2.1%.
- High Leverage and Interest: High EV/EBITDA of 20.8 and significant interest expense burden.
IRM Technical Analysis
The stock has experienced significant volatility over the past six months, declining sharply from above $100 in October 2025 to a low near $78 in December, before staging a strong recovery to recent levels. Over the short term, the stock is down 5.71% over the past month but has gained 23.13% over the past three months, significantly outperforming the broader market. The current price of $102.14 sits near the middle of its 52-week range of $72.33 to $115.24, representing a recovery from its lows but still below its recent peak.
Beta
1.15
1.15x market volatility
Max Drawdown
-25.9%
Largest decline past year
52-Week Range
$72-$115
Price range past year
Annual Return
+17.3%
Cumulative gain past year
| Period | IRM Return | S&P 500 |
|---|---|---|
| 1m | -4.2% | -4.3% |
| 3m | +24.1% | -4.0% |
| 6m | -1.4% | -2.0% |
| 1y | +17.3% | +22.2% |
| ytd | +24.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IRM Fundamental Analysis
Revenue for Q4 2025 was $1.84 billion, showing a 16.56% year-over-year growth from the same quarter in 2024. Profitability is inconsistent, with quarterly net income fluctuating from a loss of $44.9 million in Q2 2025 to a profit of $89.3 million in Q4 2025, reflecting a net margin of approximately 2.1% for the trailing period. The company's financial health is strained, with a negative debt-to-equity ratio of -19.42 and negative free cash flow of -$931.6 million over the trailing twelve months, indicating significant capital expenditures and financing activities.
Quarterly Revenue
$1.8B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$-931629000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IRM Overvalued?
Given the positive but low net margin, the trailing P/E ratio is extremely high at 169.5, while the forward P/E is 39.9, suggesting the market expects significant future earnings growth. The price-to-sales ratio is 3.55, and the EV/EBITDA is 20.8. Peer comparison data is not available in the provided inputs, so a relative industry valuation cannot be assessed.
PE
169.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -259x~36363x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.8x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is financial health. A negative debt-to-equity ratio and deeply negative free cash flow over the trailing twelve months indicate a highly leveraged capital structure and significant ongoing capital expenditures. This reliance on debt financing makes the company vulnerable to rising interest rates and could constrain future growth investments or the dividend. Furthermore, profitability is inconsistent, with quarterly net income swinging from large losses to modest profits, reflecting potential operational volatility or high fixed costs. Market risk is also present, as the stock's high valuation multiples (P/E of 169.5, EV/EBITDA of 20.8) leave little room for error; any earnings disappointment or sector rotation away from real estate could trigger a sharp correction. The lack of a detailed analyst consensus adds to the uncertainty regarding near-term price targets.
FAQ
The key risks are financial. The company has a negative debt-to-equity ratio (-19.42) and deeply negative free cash flow, indicating high leverage and heavy capital spending. Profitability is inconsistent, with quarterly net income swinging wildly. Additionally, the high valuation multiples mean the stock is vulnerable to any earnings disappointment.
The 12-month outlook is mixed with a neutral base case. The bull case target is $115-$125 if growth accelerates and leverage improves. The base case target is $95-$110, reflecting current valuation and steady execution. The bear case target is $72-$85, aligning with the 52-week low if financial risks materialize. The highest probability (50%) is assigned to the base case.
IRM appears significantly overvalued based on traditional metrics. Its trailing P/E of 169.5 is extremely high, and even its forward P/E of 39.9 implies substantial future earnings growth that may be difficult to achieve given its financial constraints. The EV/EBITDA of 20.8 is also elevated, suggesting the market is pricing in near-perfect execution.
Based on current data, IRM is not a compelling buy. While revenue growth is strong at 16.56% YoY, the stock trades at a very high trailing P/E of 169.5 and the company has negative free cash flow of -$931.6 million. The financial health is strained, making the risk high relative to the potential reward at this valuation.
IRM is more suitable for a long-term, patient investor who can tolerate high volatility and believes management will successfully de-lever the balance sheet over time. The short-term outlook is clouded by valuation and financial risk, making it a challenging trade. The 3-month outperformance of 23% may not be sustainable without fundamental improvement.